157 related articles for article (PubMed ID: 22337222)
1. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease.
Gong F; Zhang Y; Xie C; Zhu W; Wang W; Fu S; Shen H
Pediatr Res; 2012 Jun; 71(6):720-4. PubMed ID: 22337222
[TBL] [Abstract][Full Text] [Related]
2. S100A12 on circulating endothelial cells surface in children with Kawasaki disease.
Fu S; Gong F; Xie C; Zhu W; Wang W; Shen H; Tang Y
Pediatr Res; 2010 Aug; 68(2):165-8. PubMed ID: 20461025
[TBL] [Abstract][Full Text] [Related]
3. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[TBL] [Abstract][Full Text] [Related]
6. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
7. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
Qi Y; Gong F; Zhang Q; Xie C; Wang W; Fu S
Arthritis Res Ther; 2012 Nov; 14(6):R251. PubMed ID: 23171632
[TBL] [Abstract][Full Text] [Related]
8. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease.
Hirono K; Foell D; Xing Y; Miyagawa-Tomita S; Ye F; Ahlmann M; Vogl T; Futatani T; Rui C; Yu X; Watanabe K; Wanatabe S; Tsubata S; Uese K; Hashimoto I; Ichida F; Nakazawa M; Roth J; Miyawaki T
J Am Coll Cardiol; 2006 Sep; 48(6):1257-64. PubMed ID: 16979015
[TBL] [Abstract][Full Text] [Related]
9. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
10. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
11. Arterial hemodynamics in patients after Kawasaki disease.
Senzaki H; Chen CH; Ishido H; Masutani S; Matsunaga T; Taketazu M; Kobayashi T; Sasaki N; Kyo S; Yokote Y
Circulation; 2005 Apr; 111(16):2119-25. PubMed ID: 15851619
[TBL] [Abstract][Full Text] [Related]
12. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[TBL] [Abstract][Full Text] [Related]
13. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
15. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
16. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
Liu F; Ding Y; Yin W
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
18. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Lai TJ; Tang CW; Lin CC; Ho TY; Liou HH; Ger LP
J Chin Med Assoc; 2013 Aug; 76(8):438-45. PubMed ID: 23769880
[TBL] [Abstract][Full Text] [Related]
20. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
